Korean J Intern Med.  2008 Sep;23(3):156-160. 10.3904/kjim.2008.23.3.156.

Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab

• Moon SJ
• Yoon HJ
• Her SH
• Lee JM
• An HJ
• Lee YJ
• Jin SW

• KMID: 759974
• DOI: http://doi.org/10.3904/kjim.2008.23.3.156

Abstract

Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.

Keyword

Abciximab; Pericarditis

MeSH Terms

Aged
Angioplasty, Transluminal, Percutaneous Coronary/*adverse effects
Antibodies, Monoclonal/*adverse effects
Anticoagulants/*adverse effects
Cardiac Tamponade/*etiology/therapy
Emergency Medical Services
Hemorrhage/*etiology/therapy
Humans
Immunoglobulin Fab Fragments/*adverse effects
Korea
Male
Pericardiocentesis
Pericarditis/*etiology/therapy
Platelet Aggregation Inhibitors/*adverse effects
Risk Factors